Core Viewpoint - The company, Da Dongfang, reported an increase in revenue for 2024 but a significant decline in profit, indicating potential challenges in profitability despite revenue growth [1][2]. Financial Performance - The company's operating revenue for 2024 was 3.643 billion yuan, a year-on-year increase of 3.08% [2]. - The net profit attributable to shareholders was 43.638 million yuan, representing a year-on-year decrease of 72.97% [2]. - The non-recurring net profit attributable to shareholders was -38.844 million yuan, a decline of 357.07% year-on-year [2]. - Basic earnings per share were 0.05 yuan [2]. Profitability Metrics - The gross profit margin for 2024 was 15.13%, down 1.55 percentage points from the previous year [2]. - The net profit margin was 1.89%, a decrease of 2.74 percentage points compared to the same period last year [2]. Expense Management - Total operating expenses for 2024 were 461 million yuan, a decrease of 23.631 million yuan from the previous year [2]. - The expense ratio was 12.65%, down 1.06 percentage points year-on-year [2]. - Sales expenses decreased by 11.13%, management expenses decreased by 4.64%, and R&D expenses decreased by 21.06%, while financial expenses increased by 12.05% [2]. Workforce Changes - The company had 2,425 employees in 2024, a reduction of 229 employees or 8.63% compared to the end of the previous year [2]. Executive Compensation - Total compensation for directors, supervisors, and senior management in 2024 amounted to 7.296 million yuan [3]. - The highest salary was received by the general manager, who earned 1.2293 million yuan, surpassing the chairman's salary of 722,100 yuan [3]. Company Overview - Da Dongfang, established on January 20, 1998, and listed on June 25, 2002, is based in Wuxi, Jiangsu Province, and operates in retail, food production, real estate development, and healthcare [4].

Group 1 - The core viewpoint emphasizes the increasing recognition of insurance's unique role in asset allocation and wealth transfer amidst a complex economic environment, with Great Eastern Insurance emerging as a reliable choice for many families and entrepreneurs [1][3] - Great Eastern Insurance, headquartered in Singapore, benefits from the country's strict financial regulations and stable economic environment, contributing to the company's solid and robust characteristics [1][3] - The company has a long history of over a century, demonstrating a commitment to long-term strategies rather than short-term gains, which has built customer trust through stable performance during various global crises [3] Group 2 - High-net-worth individuals are attracted to Great Eastern Insurance for its comprehensive solutions aimed at wealth transfer and long-term asset protection, addressing a growing global concern [3] - The company adheres to principles of authenticity and transparency in client communication, avoiding exaggerated marketing tactics and instead sharing real customer stories, which fosters trust [3] - Backed by the strong resources of OCBC Bank, Great Eastern Insurance can offer a more integrated wealth management experience, effective risk management solutions, and personalized wealth planning services [3]

Core Points - The company announced a cash dividend of 0.03 yuan per share, approved at the 2024 annual general meeting held on May 8, 2025 [1][2] - The total number of shares eligible for the dividend distribution is 873,775,437 shares, resulting in an approximate total cash dividend payout of 26.21 million yuan [2] - The key dates for the dividend distribution include the record date on June 26, 2025, the last trading day on June 27, 2025, and the dividend payment date also on June 27, 2025 [2][3] Dividend Distribution Details - The company will only distribute cash dividends without any stock bonus or capital increase, maintaining the total number of circulating shares unchanged [2][3] - The reference price for the ex-dividend trading will be calculated using the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio), with the cash dividend being 0.03 yuan [2] - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders registered by the record date [2][3] Taxation Information - Individual shareholders holding shares for over one year will not be subject to personal income tax on the dividend, while those holding for one month or less will face a 20% tax rate on the full amount [4][5] - For qualified foreign institutional investors (QFII) and RMB qualified foreign institutional investors (RQFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.027 yuan per share [5][6] - Hong Kong investors holding shares through the "Shanghai-Hong Kong Stock Connect" will also have a 10% tax withheld, with dividends paid in RMB [6]

北京国枫律师事务所 关于无锡商业大厦大东方股份有限公司 差异化分红事项的专项核查意见 国枫律证字[2025]AN080-1 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编：100005 电话(Tel): 010—88004488/66090088 传真(Fax): 010—66090016 北京国枫律师事务所 关于无锡商业大厦大东方股份有限公司 差异化分红事项的专项核查意见 国枫律证字[2025] AN080-1 号 致:无锡商业大厦大东方股份有限公司 北京国枫律师事务所(以下简称"本所")受无锡商业大厦大东方股份有限 公司（以下简称"公司""上市公司"）委托，根据《中华人民共和国公司法》 (以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券 法》")等相关法律、法规、规章、规范性文件的有关规定,就公司 2024年年 度利润分配所涉及的差异化分红(以下简称"本次差异化分红")相关事项进行 了核查并出具本专项核查意见。 为出具本专项核查意见,本所律师特作如下声明: 1. 本所律师已根据中国证券 ...

证券代码：600327 证券简称：大东方 公告编号：2025-022 无锡商业大厦大东方股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.03元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/26 | － | 2025/6/27 | 2025/6/27 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上海证券交易所上市公司自律监管指引第 7 号--回购股份》第二十二条"上市公 司回购专用账户中的股份，不享有股东大会表决权、利润分配 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Da Dongfang, within the medical services industry [1][2] - As of June 18, the company's closing stock price was 4.65 yuan, reflecting a decrease of 1.90%, with a rolling price-to-earnings (PE) ratio of 67.28 times, and a total market capitalization of 4.114 billion yuan [1] - The average PE ratio for the medical services industry is 39.59 times, with a median of 43.15 times, positioning Da Dongfang at 35th place within the industry rankings [1][2] Group 2 - For the first quarter of 2025, Da Dongfang reported a revenue of 921 million yuan, representing a year-on-year decrease of 8.55%, while net profit was 39.932 million yuan, showing a significant year-on-year increase of 78.14%, with a sales gross margin of 19.46% [1] - The company is primarily engaged in department store retail, Sanfengqiao brand operations, and healthcare services, and has received various accolades, including being listed among the "Top 500 Private Enterprises in China" and "Top 100 Private Service Enterprises in China" [1]

Core Viewpoint - The company, 大东方, reported a stable stock price with a closing price of 4.79 yuan as of June 6, 2025, and a total market capitalization of 4.238 billion yuan, ranking 40th in the retail sector and 3387th in the A-share market [1] Company Announcements Summary - The company responded to the Shanghai Stock Exchange regarding the 2024 annual report inquiry, stating that the long-term equity investment balance is 2.486 billion yuan, with no impairment recorded [1][4] - Major investment targets include companies involved in real estate leasing, new materials development, automotive retail and maintenance, new energy vehicle investment, and real estate development and sales [1][2] - The company disclosed that the balance of other receivables for 2022 to 2024 was 60 million yuan, 9 million yuan, and 111 million yuan respectively, detailing the top five occurrences [2][3] Medical Health Business Performance - The overall revenue for the medical health business in 2024 is projected to be 2.838 billion yuan, reflecting a year-on-year growth of 8.16% with a gross margin of 7.55% [2][4] - The pediatric growth and development medical service segment benefited from the expansion of pediatric outpatient institutions and increased sales of growth hormone drugs, achieving a revenue growth of 10.33% year-on-year [2][4]

Group 1 - Company responded to the Shanghai Stock Exchange's inquiry regarding long-term equity investments, other receivables, and low gross margin in its healthcare business [1] - Company listed five investment targets in various sectors including property rights, new materials, and real estate development, asserting no need for impairment provisions [1] - Other receivables for the years 2022 to 2024 were reported as 0.6 billion, 0.09 billion, and 1.11 billion respectively, with a significant portion related to loans to Zhejiang Junxu Real Estate Development Company [1][2] Group 2 - The company reported a significant decline in profitability in 2024, with healthcare business revenue of 2.838 billion, a year-on-year increase of 8.16%, and a gross margin of 7.55% [2] - The gross margin for the healthcare segment has been affected by various factors, including the introduction of new disciplines and changes in medical insurance policies [3] - The average gross margin for the company's hospitals has decreased over the past three years, primarily due to the impact of medical insurance reforms and drug procurement policies [3] Group 3 - The company noted that the gross margin for its pediatric growth and development services has gradually increased but remains low, primarily due to high costs associated with growth hormone treatments [3] - The market for long-acting growth hormones is expected to expand as public awareness of children's height management increases [4] - Currently, only 5% of patients express a willingness to undergo treatment, indicating significant growth potential in the market [4]

Core Viewpoint The audit firm Gongzheng has conducted a thorough review of Wuxi Commercial Building Dae Dong Co., Ltd.'s long-term equity investments and financial disclosures, concluding that there are no impairment indicators for these investments, and the financial health of the associated companies remains stable. Group 1: Long-term Equity Investments - The company's long-term equity investment balance as of 2024 is RMB 2.486 billion, with no impairment recognized in the past three years [2][3] - Significant investments include RMB 600 million in Shanghai Jidaohang New Energy Development Partnership, which has been ongoing since 2022 [2][3] - The audit firm has requested detailed disclosures regarding the investment structures, cash flows, and financial performance of the companies involved [2][3] Group 2: Financial Performance of Invested Companies - Wuxi Sanfeng Building Management Co., Ltd. reported revenues of RMB 151.17 million and a net loss of RMB 399.28 million over the past three years, with stable asset values [4][5] - Anhui Tao-Liu New Materials Research Institute has faced continuous losses, prompting the company to exit its investment in early 2025 [6][7] - Wuxi Commercial Building Group Dae Dong Automobile Co., Ltd. has shown stable profitability with net profits of RMB 18.73 million, RMB 19.94 million, and RMB 21.59 million over the last three years [5][8] Group 3: Investment Strategy and Market Position - The investment in Shanghai Jidaohang focuses on the rapidly growing new energy vehicle sector, aligning with national strategic initiatives for carbon neutrality [8][9] - Jidaohang has established a comprehensive investment structure in the new energy vehicle industry, with significant investments in companies like Shanghai Jixiang Zhichu and Yundu Automobile [9][10] - The governance structure of Jidaohang ensures professional and standardized investment processes, with no identified risks of fund misappropriation [20][24] Group 4: Cash Flow and Investment Activities - The company has reported cash outflows for investment activities totaling RMB 60 million over the past three years, with no indications of fund misappropriation [21][22] - The cash flow from investment activities includes significant payments for fixed assets and equity acquisitions, reflecting a strategic focus on growth and stability [21][22] - The audit firm has confirmed that the investment activities align with the company's strategic objectives and financial health [22][24]

股票代码：600327 股票简称：大东方 公告编号：临 2025－021 无锡商业大厦大东方股份有限公司 关于《上海证券交易所关于公司 2024 年年度报告的 信息披露监管问询函》的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 无锡商业大厦大东方股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日收到《上海证券交易所关于无锡商业大厦大东方股份有限公司 2024 年年度报 告的信息披露监管问询函》（上证公函【2025】0539 号）（以下简称"《问询 函》"）。根据《问询函》的要求，公司会同公证天业会计师事务所（特殊普通 合伙）年审会计师对《问询函》所列事项逐一复核落实，现就《问询函》所列事 项逐项回复并说明如下（除特别注明外，以下金额单位为人民币万元）： 问题一、关于长期股权投资。 根据年报，2024 年公司长期股权投资余额为 24.86 亿元，近三年未计提减值。 其中对上海吉道航新能源发展合伙企业（有限合伙）（以下简称吉道航新能源） 长期股权投资 6 亿元，主要系 2022 年起陆续投资。投资 ...